Efficacy and Safety of Carvedilol in Treatment of Heart Failure with Chronic Kidney Disease
- 1 January 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Heart Failure
- Vol. 4 (1), 18-26
- https://doi.org/10.1161/circheartfailure.109.932558
Abstract
Background—: The safety and efficacy of different types of β-blocker therapy in patients with non–dialysis-dependent chronic kidney disease (CKD) and systolic heart failure (HF) are not well described. We assessed whether treatment of systolic HF with carvedilol is efficacious and safe in adults with CKD. Methods and Results—: We performed a post hoc analysis of pooled individual patient data (n=4217) from 2 multinational, double-blinded, placebo-controlled, randomized trials, CAPRICORN (Carvedilol Postinfarct Survival Control in Left Ventricular Dysfunction Study) and COPERNICUS (Carvedilol Prospective Randomized, Cumulative Survival study). Primary outcome was all-cause mortality. Secondary outcomes included cardiovascular mortality, HF mortality, first HF hospitalization, the composite of cardiovascular mortality or first HF hospitalization, and sudden cardiac death. Non–dialysis-dependent CKD was defined by estimated glomerular filtration rate ≤60 mL/min/1.73 m 2 , using the abbreviated Modification of Diet in Renal Disease equation. CKD was present in 2566 of 4217 (60.8%) of the cohort, 50.4% of whom were randomly assigned to carvedilol therapy. Within the CKD group, treatment with carvedilol decreased the risks of all-cause mortality (hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.63 to 0.93; P =0.007), cardiovascular mortality (HR, 0.76; 95% CI, 0.62 to 0.94; P =0.011), HF mortality (HR, 0.68; 95% CI, 0.52 to 0.88; P =0.003), first hospitalization for HF (HR, 0.74; 95% CI, 0.61 to 0.88; P =0.0009), and the composite of cardiovascular mortality or HF hospitalization (HR, 0.75; 95% CI, 0.65 to 0.87; P P =0.098). There was no significant interaction between treatment arm and study type. Carvedilol was generally well tolerated by both groups of patients, with an increased relative incidence in transient increase in serum creatinine without need for dialysis and other electrolyte changes in the CKD patients. However, in a sensitivity analysis among HF subjects with estimated glomerular filtration rate 2 (CKD stage 3b), the efficacy of carvedilol was not significantly different from placebo. Conclusions—: This analysis suggests that the benefits of carvedilol therapy in patients with systolic left ventricular dysfunction with or without symptoms of HF are consistent even in the presence of mild to moderate CKD. Whether carvedilol therapy is similarly efficacious in HF patients with more advanced kidney disease requires further study.Keywords
This publication has 45 references indexed in Scilit:
- Reduced Kidney Function as a Risk Factor for Incident Heart FailureJournal of the American Society of Nephrology, 2007
- American Society of Nephrology Presidential Address 2006Journal of the American Society of Nephrology, 2007
- Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart FailureCirculation, 2006
- National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and StratificationAnnals of Internal Medicine, 2003
- Burden of Systolic and Diastolic Ventricular Dysfunction in the CommunityJAMA, 2003
- Long-Term Trends in the Incidence of and Survival with Heart FailureThe New England Journal of Medicine, 2002
- Heart Failure — An Epidemic of Uncertain ProportionsThe New England Journal of Medicine, 2002
- Renal Function, Neurohormonal Activation, and Survival in Patients With Chronic Heart FailureCirculation, 2000
- The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunctionJournal of the American College of Cardiology, 2000
- Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: Results from the Studies of Left Ventricular Dysfunction (SOLVD)American Heart Journal, 1999